A股異動丨萬孚生物(300482.SZ)大跌近8% 召回4批次瘧原蟲檢測試劑
格隆匯9月7日丨萬孚生物(300482.SZ)大跌近8%,報92.88元,總市值318億元。廣東省藥品監督管理局網站於9月3日發佈了廣州萬孚生物技術股份有限公司對瘧原蟲檢測試劑(膠體金法)主動召回的公告。日前,上市企業萬孚生物報告,發現部分批次瘧原蟲檢測試劑(膠體金法)產品技術表述與國家參考品的要求存在偏差。萬孚生物對其生產的瘧原蟲檢測試劑(膠體金法)(註冊證號:國械注準20153400610)主動召回。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.